‘Female Viagra’ drug, Addyi, receives FDA nod

The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi's approval, there were no FDA-approved treatments for sexual desire disorders in men or women. "Today's approval provides women distressed by their low sexual desire with an approved treatment option," said ["]